Bevacizumab

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Ipilimumab (抗 CTLA-4) 是一种针对细胞表面抗原 CTLA-4 的免疫调节性单克隆抗体，也是一种免疫检查点抑制剂。 Bevacizumab 是一种人源化单克隆抗体，以高亲和力特异性结合所有 VEGF-A 亚型。

Ipilimumab anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.Bevacizumab a humanized monoclonal antibody specifically binds to all VEGF-A isoforms with high affinity.

Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity, and inhibits its interaction with VEGFR-1 and VEGFR-2. Experimental analysis shows that the EC50 of Bevacizumab to bind VEGF analyzed by ELISA is 0.18 μg/mL. Binding kinetics assays show similar results that Bevacizumab inhibits the VEGF-induced proliferation of HUVEC with an IC50 value of 0.047±0.0081 μg/mL.

It is demonstrated that the subconjunctival administration of FD006 and Bevacizumab can significantly inhibit CoNV in NaOH cauterized rats compared with the control group (p?

——

Angiogenesis

VEGFR

VEGFR

——

——

216974-75-3

149 kDa

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years